• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»type 2 diabetes mellitus

Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?

By Pallavi Madhiraju on April 27, 2026   Pharma & Biotech  

Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?

Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.

Recent Posts

  • Why BrioHealth’s Brio4Kids trial could become a test case for pediatric LVAD innovation
  • Why Humacyte, Inc.’s vascular tissue platform is gaining attention in high-risk dialysis populations
  • What ZORYVE cream’s infant indication means for non-steroidal eczema treatments
  • Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
  • Why Pacira BioSciences, Inc. is positioning EXPAREL as a cost-saving tool in Medicare surgery
  • Is direct-to-patient pharma becoming the industry’s answer to drug pricing pressure?
  • Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
  • Why the Veradermics hair loss trial is bigger than another aesthetics readout
  • Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?
  • Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma
  • Why Pulse Biosciences’ 12-month nsPFA data matters in a PFA market dominated by Farapulse and Affera
  • Adagio Medical reports pivotal FULCRUM-VT results as FDA pathway sharpens for vCLAS ablation system
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes